Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere

索拉非尼 肝细胞癌 瑞戈非尼 卡波扎尼布 医学 伦瓦提尼 催眠药 内科学 肿瘤科 临床试验 癌症 结直肠癌
作者
Jean‐Luc Raoul,Julien Edeline
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (4): 479-481 被引量:38
标识
DOI:10.1016/s1470-2045(20)30082-6
摘要

Hepatocellular carcinoma is the fifth most common cancer and second leading cause of cancer-related death globally. More than half of all patients are in China. For nearly 10 years, sorafenib was the only drug to have shown survival benefit in advanced hepatocellular carcinoma. 1 Llovet JM Ricci S Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390 Crossref PubMed Scopus (9037) Google Scholar , 2 Cheng AL Kang YK Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34 Summary Full Text Full Text PDF PubMed Scopus (4450) Google Scholar Regorafenib, lenvatinib, cabozantinib, and ramucirumab have given positive results in phase 3 trials. From 2008 to 2017, however, many phase 3 trials testing new drugs in first or second lines failed, despite promising results observed in the early phases. Reasons for those failures have been discussed previously: poor understanding of drivers of progression, flaws in trial design, underestimation of liver toxicity, marginal antitumour activity, and an absence of trial enrichment with adequate biomarkers of benefit. 3 Llovet JM Hernandez-Gea V Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20: 2072-2079 Crossref PubMed Scopus (308) Google Scholar Many histology-based, molecular-based or immune-based classifications have now been published to assist that enrichment. 4 Llovet JM Montal R Sia D Finn RS Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15: 599-616 Crossref PubMed Scopus (927) Google Scholar Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trialCamrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients. Full-Text PDF

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sendou的应助被科研通管家采纳,获得60
刚刚
千千完成签到,获得积分10
刚刚
刚刚
刚刚
爆米花的应助被科研通管家采纳,获得10
刚刚
天天快乐的应助被科研通管家采纳,获得10
刚刚
顾矜的应助被科研通管家采纳,获得10
刚刚
彭于彦祖的应助被科研通管家采纳,获得50
刚刚
刚刚
在水一方的应助被科研通管家采纳,获得10
1秒前
我是老大的应助被科研通管家采纳,获得10
1秒前
cwx完成签到,获得积分10
1秒前
酷波er的应助被重要的洪纲采纳,获得10
1秒前
酷波er的应助被科研通管家采纳,获得10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
1秒前
Owen的应助被莉莉安采纳,获得10
1秒前
秋风的应助被清爽笙采纳,获得100
1秒前
香蕉觅云的应助被科研通管家采纳,获得10
1秒前
molihuakai的应助被科研通管家采纳,获得10
2秒前
Ava的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
小白菜发布了新的文献求助10
2秒前
wrwywzx发布了新的文献求助10
2秒前
小蘑菇的应助被稳重紫蓝采纳,获得10
3秒前
氧化钙发布了新的文献求助10
3秒前
3秒前
zaq66996发布了新的文献求助10
3秒前
3秒前
kinji发布了新的文献求助10
4秒前
lsl完成签到,获得积分10
4秒前
han发布了新的文献求助10
4秒前
dyuwgeuo完成签到,获得积分10
5秒前
5秒前
hxhx完成签到,获得积分10
5秒前
5秒前
动听的念文完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182602
求助须知:如何正确求助?哪些是违规求助? 9572033
关于积分的说明 21821767
捐赠科研通 7779061
什么是DOI,文献DOI怎么找? 3433684
关于科研通互助平台的介绍 2557863
邀请新用户注册赠送积分活动 2479732